Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma

Join us as Brooke Peters, PharmD, BCOP, the Clinical Pharmacy Services Manager of Pharmacy Operations at the American Oncology Network, shares insights on key considerations for operationalizing bispecific therapies for patients with relapsed or refractory multiple myeloma (RRMM). The broadcast will explore three states of readiness that can support successful operations: facility readiness, provider and care team readiness, and patient and care partner readiness.